The Hunt for the Magic Bullet 2.0 – A New Precision Treatment for Cancer in Dogs
Project overview
Participants
More related research
Global goals
- 3. Good health and well-being
- 9. Industry, innovation and infrastructure
- 10. Reduced inequalities
Short summary
The project is evaluating OXC-101, a new oral cancer treatment for dogs with lymphoma, hemangiosarcoma, and mammary tumors. The goal is to develop a gentler, more targeted treatment to be administered at home, while also identifying biomarkers that can advance veterinary and human cancer research.
Background
Cancer is one of the leading causes of death in dogs and poses a major welfare issue. Current treatments often involve intravenous chemotherapy at veterinary hospitals, which can cause significant side effects and require repeated visits. At the same time, we know that spontaneously occurring tumors in dogs often resemble human cancer more closely than many laboratory models, making dogs important in comparative oncology and One Health research as well.
Aim
The project will evaluate OXC-101 (karonudib), a new oral drug candidate for cancer, in dogs with three severe tumor diseases: lymphoma, hemangiosarcoma, and mammary tumors. We want to investigate whether the treatment can become a safer and more targeted alternative that can be administered at home, offering a better quality of life for both the dog and the owner.
Goals
The goal is to study both the safety and clinical efficacy of the treatment and to link tumor tissue and blood-based biomarkers to treatment response and resistance. In this way, we aim to identify which patients benefit most from the treatment and lay the groundwork for more personalized cancer treatment in veterinary medicine. The project also has a clear translational ambition, where the results can contribute to improved study design and biomarkers in human oncology as well.
Collaborations
In addition to participating researchers from SLU, the project group also includes the following:
- Thomas Helleday, Karolinska Institutet
- Kumar Sanjiv, Djuriverse Veterinary Clinic
as well as biostatistical expertise associated with the project at SLU